公告称，收入增加主要是由于于报告期内，集团的VitaFlow Liberty®经导管主动脉瓣膜及可回收输送系 统在全球商业化方面的持续推进促进了海外收入的大幅增长;及集团的AnchorMan®左心耳封堵系统及 AnchorMan®左心耳导引系统在中国和海外的商业化进展稳步推进。 智通财经APP讯，心通医疗-B(02160)发布截至2025年6月30日止6个月的中期业绩，该集团取得收入2.29 亿元，同比增加2.67%;公司权益股东应占亏损216.3万元，同比减少96.17%;每股基本亏损0.09分。 ...

Core Viewpoint - The company anticipates a significant reduction in net loss for the first half of the year, projecting a loss not exceeding RMB 10 million, which represents a decrease of at least 83% compared to the same period last year [1] Group 1: Financial Performance - The expected net loss for the reporting period is projected to be less than RMB 10 million, marking a reduction of no less than 83% [1] - The reduction in net loss is primarily attributed to the sales of the VitaFlow Liberty® transcatheter aortic valve and its delivery system, which have been sold in over 20 countries/regions overseas, resulting in more than a twofold increase in overseas revenue compared to the same period last year [1] Group 2: Product Development and Commercialization - The AnchorMan® left atrial appendage occluder system and its delivery system are making steady progress in commercialization in China, having received CE marking and achieved commercialization in Europe during the reporting period, contributing to revenue growth [1] Group 3: Operational Efficiency - The company has enhanced operational efficiency through continuous optimization of resource allocation and active cost management measures [1] - The company's associate, 4C Medical Technologies, Inc, completed a Series D financing round, resulting in a decrease in the company's equity stake in 4C Medical, which is recognized as a gain from the partial sale of equity [1]

【财华社讯】心通医疗-B(02160.HK)公布，预期截至2025年6月30日止六个月录得净亏损不高于人民币 1000万元，较2024年同期减少不低于83%。该等净亏损减少主要是由于VitaFlow Liberty®经导管主动脉 瓣膜及可回收输送系统已在海外20余个国家/地区实现销售，来自海外的收入较截至2024年6月30日止六 个月增长两倍以上；AnchorMan®左心耳封堵器系统及其导引系统在中国的商业化进展稳步推进，并于 报告期內获得CE标志并在欧洲实现商业化，共同贡献了收入增量；持续优化资源配置、积极管控各项 费用等措施进一步提升运营效率；及联营公司4C Medical完成D轮融资， 集团于4C Medical的股权比例 下降，获得视作出售部分股权收益。 本文源自：财华网 ...

Core Viewpoint - The company expects to achieve a net loss of no more than RMB 10 million in the first half of 2025, representing a year-on-year reduction of not less than 83% [1] Group 1: Financial Performance - The reduction in net loss is primarily attributed to the sales of VitaFlow Liberty® transcatheter aortic valve and its delivery system in over 20 countries/regions, with overseas revenue increasing by more than two times year-on-year [1] - The commercial progress of the AnchorMan® left atrial appendage occluder system and its guiding system in China is steadily advancing, having obtained CE marking and commercialized in Europe during the reporting period, contributing to revenue growth [1] Group 2: Operational Efficiency - The company has enhanced operational efficiency through continuous optimization of resource allocation and active cost management measures [1] - The company's associate, 4C Medical Technologies, Inc, completed a Series D financing round, resulting in a decrease in the company's equity stake in 4C Medical, which generated income from the sale of part of its equity [1]

Group 1 - The biopharmaceutical B-class stocks experienced a rally, with notable increases in stocks such as Clover Biopharma-B, Kelun-Biotech, and Xintong Medical-B, the latter seeing a peak increase of nearly 21% before settling at over 6% [2] - The surge in Xintong Medical's stock price is attributed not only to sector trends but also to the news that MicroPort Medical is considering merging its CRM business with Xintong Medical [2] - MicroPort Medical's stock also saw a significant increase, jumping nearly 7% on the same day [3] Group 2 - On July 16, Xintong Medical announced that its board received a non-binding proposal from its controlling shareholder, MicroPort Medical, regarding a strategic restructuring of the CRM business [4] - MicroPort Medical's CRM business focuses on developing, manufacturing, and selling products for diagnosing and managing arrhythmias and heart failure, including pacemakers and defibrillators [4] - The merger aims to enhance internal resource integration, improve competitiveness, and create long-term value for the group and its stakeholders [4] Group 3 - The merger is expected to create a comprehensive cardiac product platform, offering a diverse range of products from CRM solutions to structural heart disease products [6] - By establishing this diversified product platform, the group aims to enhance its global market development capabilities and strengthen its positioning in respective segments [6] - The merger is also anticipated to generate synergies through shared international marketing and sales channels, expanding business scale and growth potential [6] Group 4 - Overall, the merger represents an internal business adjustment for MicroPort Medical, aimed at consolidating cardiac-related operations and fostering collaborative development [7] - Both MicroPort Medical and Xintong Medical are currently in a loss-making position, and this restructuring may help them achieve profitability sooner [7] - Market feedback has been positive, with both companies' stock prices rising, although Xintong Medical's stock experienced a significant pullback, indicating some divergence in investor sentiment [8]